Media headlines about Johnson & Johnson (NYSE:JNJ) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Johnson & Johnson earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.0841990630759 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s analysis:
- The Outlook For Johnson & Johnson’s Immunology Drug Business (trefis.com)
- UPDATE 1-Jury orders Bayer, J&J to pay $28 million in Xarelto lawsuit (BAYN, JNJ) (markets.businessinsider.com)
- Johnson & Johnson to launch JLABS center in Shanghai (massdevice.com)
- Biotech Stocks May See a New M&A Wave in 2018 (finance.yahoo.com)
- The Outlook For Johnson & Johnson’s Immunology Drug Business (finance.yahoo.com)
Johnson & Johnson (JNJ) traded down $0.97 during trading hours on Tuesday, reaching $139.01. The company’s stock had a trading volume of 5,916,600 shares, compared to its average volume of 5,873,962. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. The stock has a market cap of $375,900.00, a price-to-earnings ratio of 19.60, a P/E/G ratio of 2.85 and a beta of 0.80.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.42%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.
Several equities analysts recently weighed in on the company. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target for the company in a research note on Monday, October 30th. Citigroup lifted their price target on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Jefferies Group lifted their price target on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, October 16th. Finally, Barclays lifted their price target on Johnson & Johnson from $140.00 to $148.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 18th. Four analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $144.59.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.